natgillin/translations-raw huggingface dataset:
- Epilepsy or other seizure disorders, not controlled by medicine - Heart problems, which can cause symptoms such as chest pain (angina), particularly after any activity; swollen ankles, shortness of breath (congestive heart failure); or an irregular heartbeat (arrhythmia). 
Time se smanjuje rizik od reakcija na mjestu davanja injekcije. - epilepsiju ili ostale poremećaje s napadajima, koji nisu kontrolirani lijekovima - tegobe sa srcem, koje mogu uzrokovati simptome poput boli u prsištu (angina), posebno nakon neke aktivnosti; oticanje gležnjeva, nedostatak zraka (kongestivno zatajenje srca); ili nepravilan srčani ritam (aritmiju) - tegobe sa štitnjačom - nizak broj bijelih krvnih stanica ili trombocita, koji mogu uzrokovati povećani rizik od infekcije ili krvarenja
Laboratory abnormalities 
Abnormalnosti u laboratorijskim nalazima
For more information see section 5.1. 
Za više informacija vidjeti dio 5.1. Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
• 1 Plegridy Pen (see Figure A) 
• 1 brizgalica Plegridy (pogledajte sliku A)
Step 3: Check your Plegridy pen (see Figure C) 
3. korak: Provjerite brizgalicu Plegridy (pogledajte sliku C)
83% treatment-naïve patients 
83% bolesnika koji prethodno nisu bili liječeni
Elevated serum hepatic transaminase levels, hepatitis, autoimmune hepatitis and rare cases of severe hepatic failure have been reported with interferon beta medicinal products. 
Povišene razine jetrenih transaminaza, hepatitis, autoimuni hepatitis i rijetki slučajevi teškog zatajenja jetre zabilježeni su s lijekovima koji sadrže interferon beta.
- If any of these effects trouble you, contact a doctor. 
Ako primijetite bilo koju od ovih nuspojava, obratite se liječniku.
Patients should be monitored for signs of hepatic injury (see section 4.8). 
Kod bolesnika treba pratiti pojavu znakova oštećenja jetre (vidjeti dio 4.8).
Choose the correct pen from a pack. 
Odaberite ispravnu brizgalicu iz pakiranja
No data are available from clinical efficacy/safety studies directly comparing pegylated with non-pegylated interferon beta-1a, or from patients switching between non-pegylated and pegylated interferon. 
Nema podataka iz ispitivanja za kliničku djelotvornost i sigurnost koja bi izravno uspoređivala pegilirani s nepegiliranim interferonom beta-1a, ili kod bolesnika koji su prebacivani s nepegiliranog na pegilirani interferon.
The incidence of cardiovascular events was similar between Plegridy (125 micrograms every 2 weeks) and placebo treatment groups (7% in each group). 
Incidencija kardiovaskularnih događaja bila je slična između skupine koja je primala Plegridy (125 mikrograma svaka 2 tjedna) i skupine koja je primala placebo (7% u svakoj skupini).
Patients should be monitored for signs of hepatic injury and caution exercised when interferons are used concomitantly with other medicinal products associated with hepatic injury (see sections 4.8 and 5.2). 
Bolesnike treba pratiti na simptome oštećenja jetre, a naročito je potreban oprez ako uzimaju interferone zajedno s drugim lijekovima koji su povezani s oštećenjem jetre (vidjeti dijelove 4.8 i 5.2).
• The liquid is coloured, cloudy or contains floating particles. 
• ako je tekućina obojena, zamućena ili sadrži plutajuće čestice.
The other ingredients are: Sodium acetate trihydrate, acetic acid glacial, arginine hydrochloride, polysorbate 20 and water for injections (see Section 2 “Plegridy contains sodium”). 
Drugi sastojci su: natrijev acetat trihidrat, acetatna kiselina ledena, argininklorid, polisorbat 20 i voda za injekcije (pogledajte dio 2 „Plegridy sadrži natrij“).
1512 patients were randomised to and dosed with 125 micrograms Plegridy injected subcutaneously every 2 (n=512) or 4 (n=500) weeks versus placebo (n=500). 
Randomizirano je 1512 bolesnika koji su primali dozu od 125 mikrograma Plegridyja injiciranog supkutano svaka 2 (n=512) ili 4 (n=500) tjedna u usporedbi s placebom (n=500).
Let the pen warm to room temperature for at least 30 minutes. 
Ostavite brizgalicu najmanje 30 minuta na sobnoj temperaturi da se zagrije.
Mean white blood cell counts remained within normal limits in patients treated with Plegridy. 
Srednja vrijednost broja leukocita ostala je u granicama normale u bolesnika liječenih Plegridyjem.
Plegridy also significantly reduced the risk of relapse by 39% (p=0.0003), the risk of sustained disability progression confirmed at 12 weeks by 38% (p=0.0383) and at 24 weeks (post-hoc analysis) by 54% (p=0.0069), the number of new or newly enlarging T2 lesions by 67% (p<0.0001), the number of Gd-enhancing lesions by 86% (p<0.0001) and the number of new T1 hypointense lesions compared to placebo by 53% (p<0.0001). 
Plegridy je također značajno smanjio rizik od relapsa za 39% (p=0,0003), rizik od kontinuirane progresije onesposobljenosti potvrđen nakon 12 tjedana za 38% (p=0,0383) i nakon 24 tjedna (post hoc analiza) za 54% (p=0,0069), broj novih ili novo povećanih T2 lezija za 67% (p<0,0001), broj
Plegridy can be stored at room temperature (up to 25°C) for up to 30 days as long as it is stored away from light. 
Plegridy se može čuvati na sobnoj temperaturi (do 25°C) do 30 dana ako se čuva zaštićen od svjetlosti.
A single-dose study in healthy subjects and subjects with various degrees of renal impairment (mild, moderate, and severe renal impairment as well as subjects with end state renal disease) showed a fractional increase in AUC (13-62%) and Cmax (42-71%) in subjects with mild (estimated glomerular filtration rate 50 to ≤80 mL/min/1.73m2), moderate (estimated glomerular filtration rate 30 to <50 mL/min/1.73m2), and severe (estimated glomerular filtration rate <30 mL/min/1.73m2) renal impairment, compared to subjects with normal renal function (estimated glomerular filtration rate >80 mL/min/1.73m2). 
(blago, umjereno i teško oštećenje funkcije bubrega, kao i ispitanici s terminalnim stanjem bubrežne bolesti) pokazali su frakcijsko povećanje AUC-a (13-62%) i Cmax (42-71%) u ispitanika s blagim oštećenjem bubrega (procijenjena stopa glomerularne filtracije 50 do ≤80 ml/min/1,73 m2), umjerenim oštećenjem bubrega (procijenjena stopa glomerularne filtracije 30 do <50 ml/min/1,73 m2) i teškim oštećenjem bubrega (procijenjena stopa glomerularne filtracije <30 ml/min/1,73 m2), u odnosu na ispitanike s normalnom bubrežnom funkcijom (procijenjena stopa glomerularne filtracije
- If you are unsure of the number of days you have kept a pen out of the fridge, throw the pen away. 
Ako niste sigurni koliko je dugo brizgalica bila izvan hladnjaka, tada bacite tu brizgalicu.
One injection of Plegridy 125 micrograms every 14 days (every two weeks). 
Jedna injekcija Plegridyja od 125 mikrograma svakih 14 dana (svaka 2 tjedna).
Hepatic transaminase abnormalities 
Abnormalnosti jetrenih transaminaza
Do not touch or blow this area again before giving the injection. 
Nemojte ponovno dotaknuti to mjesto prije davanja injekcije.
Therefore if clinical features of TMA are observed, further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. 
Stoga, ako su opažena klinička obilježja TMA, peporučuje se daljnje testiranje razine trombocita u krvi, LDH u serumu, krvnih razmaza i bubrežne funkcije.
This medicinal product contains less than 1 mmol (23 mg) sodium, that is to say it is essentially “sodium-free”. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija, tj. zanemarive količine natrija.
Plegridy is a clear and colourless solution for injection in a glass pre-filled syringe with an attached needle. 
Plegridy je bistra i bezbojna otopina za injekciju u staklenoj napunjenoj brizgalici s pričvršćenom iglom.
(may affect up to 1 in 100 people) - Hives - Changes in your blood which might cause unexplained bruising or bleeding. 
Manje česte nuspojave (mogu se pojaviti u manje od 1 na 100 osoba) - koprivnjača - promjene u krvi koji bi mogle izazvati neobjašnjive modrice ili krvarenje
This medicine contains less than 1 mmol sodium (23 mg), that is to say it is essentially “sodium-free”. 
Ovaj lijek sadrži manje od 1 mmol natrija (23 mg), tj. zanemarive količine natrija.
Plegridy 125 micrograms every 4 weeks 
Plegridy 125 mikrograma svaka 4 tjedna
You must only inject Plegridy once every 2 weeks. 
Smijete primijeniti samo jednu injekciju Plegridyja svaka 2 tjedna.
The dose indicates the quantity of the interferon beta-1a moiety of peginterferon beta-1a without consideration of the PEG moiety attached. 
Doza označava količinu interferona beta-1a u peginterferonu beta-1a, bez uzimanja u obzir vezane PEG skupine.
- Throw away any pen that is kept out of the fridge for more than 30 days. 
- Bacite brizgalicu koja je bila izvan hladnjaka više od 30 dana.
Do not use your syringe if it has been dropped or is visibly damaged. 
Nemojte upotrijebiti štrcaljku ako Vam je ispala ili ima vidljiva oštećenja.
Do not share your Plegridy pre-filled syringe with anyone else to avoid giving an infection to them or getting an infection from them. 
Nemojte ni s kim dijeliti svoju napunjenu štrcaljku Plegridyja kako ne biste prenijeli ili dobili neku infekciju.
Solution for injection 2 pre-filled syringes 6 pre-filled syringes 
Otopina za injekciju 2 napunjene štrcaljke 6 napunjenih štrcaljki
- Plegridy can be kept outside a fridge at room temperature (up to 25°C) for up to 30 days but it must be kept away from light. 
- Plegridy se može čuvati izvan hladnjaka na sobnoj temperaturi (do 25°C) do 30 dana, ali se mora čuvati zaštićen od svjetlosti.
Plegridy is interferon beta-1a conjugated to a single, linear 20 kDa methoxy poly(ethyleneglycol) molecule at the alpha-amino group of the N-terminal amino acid residue. 
Plegridy je interferon beta-1a konjugiran s jednom, linearnom molekulom metoksipoli(etilenglikola) od 20 kDa na alfa-amino skupini N-terminalnog kraja aminokiseline.
Hepatic function 
Jetrena funkcija
• For the Initiation Pack injections, you can use the record table printed on the inside of the lid of the Initiation Pack. 
• Za injekcije iz pakiranja za početak liječenja možete koristiti tablicu za bilježenje koja je otisnuta na unutarnjem dijelu poklopca pakiranja za početak liječenja.
Supplies needed for your Plegridy Pen injection: 
Pribor potreban za injekciju pomoću brizgalice Plegridy:
- Blood clots in the small blood vessels may occur during your treatment. 
- Tijekom liječenja mogu se pojaviti krvni ugrušci u malim krvnim žilama.
Plegridy 125 micrograms every 2 weeks 
Plegridy 125 mikrograma svaka 2 tjedna
The recommended dose of Plegridy is 125 micrograms injected subcutaneously every 2 weeks (14 days). 
Preporučena doza Plegridyja je 125 mikrograma primijenjeno supkutanom injekcijom svaka 2 tjedna (14 dana).
c. Let your injection site dry on its own before injecting your dose. 
c. Pustite da se mjesto za injekciju samo osuši prije ubrizgavanja doze.
• Let the Plegridy pre-filled syringe warm to room temperature for at least 30 minutes. 
• Ostavite napunjenu štrcaljku Plegridyja najmanje 30 minuta na sobnoj temperaturi da se zagrije.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MULTIPACK OUTER CARTON Pre-filled pen 125 mcg Multipack (with bluebox) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA VIŠESTRUKOG PAKIRANJA Višestruko pakiranje napunjene brizgalice od 125 μg (s plavim okvirom)
Do not use external heat sources such as hot water to warm the Plegridy pre-filled syringe. 
Nemojte koristiti vanjske izvore topline poput vruće vode kako biste zagrijali napunjenu štrcaljku Plegridyja.
How to Inject Plegridy 
Kako ubrizgati Plegridy
• If needed, Plegridy may be stored in the closed original carton without refrigeration up to 25°C for up to 30 days. 
• Po potrebi se Plegridy može čuvati u zatvorenoj originalnoj kutiji izvan hladnjaka na temperaturi do 25°C najdulje 30 dana.
Full dose injection: 125 micrograms, choose grey syringe 
Injekcija pune doze: 125 mikrograma, izaberite sivu štrcaljku
Neopterin concentrations return to baseline after the two week dosing interval. 
Koncentracije neopterina se vraćaju na početno stanje nakon 2-tjednog intervala doziranja.
*The active substance, peginterferon beta-1a, is a covalent conjugate of interferon beta-1a, produced in Chinese Hamster Ovary cells, with 20,000 Dalton (20 kDa) methoxy poly(ethyleneglycol) using an O-2-methylpropionaldehyde linker. 
*Djelatna tvar, peginterferon beta-1a, kovalentni je konjugat interferona beta-1a proizvedenog u stanicama jajnika kineskog hrčka, s metoksipolietilenglikolom od 20 000 Daltona (20 kDa) preko poveznika O-2-metilpropionaldehida.
Do not share your Plegridy pen. 
Nemojte dijeliti s drugima svoju brizgalicu Plegridy.
Do not remove the cap until you are ready to inject. 
Nemojte skidati kapicu prije nego što budete spremni dati injekciju.
Read the instructions in section 7 “Instructions for injecting Plegridy pre-filled syringe” at the end of this leaflet before you start using Plegridy. 
Pročitajte upute u dijelu 7 „Upute za ubrizgavanje Plegridyja u napunjenoj štrcaljki“ na kraju ove upute prije nego što počnete koristiti Plegridy.
Syringe label 
Oznaka štrcaljke
Following repeated subcutaneous administration of peginterferon beta-1a in rhesus monkeys at doses up to 400-fold (based on exposure, AUC) the recommended therapeutic dose; no effects other than the known mild pharmacological responses by rhesus monkeys to interferon beta-1a were observed after the first and second weekly dose. 
(na temelju izloženosti, AUC) većima od preporučene terapijske doze; nije bilo drugih učinka osim poznatih blagih farmakoloških odgovora rezus majmuna na interferon beta-1a opaženih poslije prve i druge tjedne doze.
Box of two or six 125 microgram pre-filled syringes (grey labelled syringes) in sealed plastic trays. 
Kutija s dvije ili šest napunjenih štrcaljki od 125 mikrograma (sivo označene štrcaljke) u zatvorenim plastičnim spremnicima.
• Keep Plegridy pre-filled syringe and all medicines out of reach of children. 
• Čuvajte štrcaljku Plegridyja i sve lijekove izvan dohvata djece.
Nephrotic syndrome, glomerulosclerosis 
Poremećaji bubrega i mokraćnog sustava nefrotski sindrom, glomerulonefritis rijetko
Consider the timing of your Plegridy injection. 
Vodite računa o tome kada ćete primijeniti injekciju Plegridyja.
Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with interferon beta-products. 
Plućna arterijska hipertenzija uočena je u različitim vremenskim točkama tijekom liječenja, i do nekoliko godina nakon početka liječenja lijekovima koji sadrže interferon beta.
The active substance in Plegridy is peginterferon beta-1a. 
Djelatna tvar u Plegridyju je peginterferon beta-1a.
Plegridy binds to the type I interferon receptor on the surface of cells and elicits a cascade of intracellular events leading to the regulation of interferon-responsive gene expression. 
I na površini stanica, te izaziva slijed intracelularnih zbivanja vodeći do ekspresije gena koje regulira interferon.
Pre-Filled Syringe 125 mcg 
Napunjena brizgalica 125 μg
Box of two 125 microgram pre-filled pens (grey labelled pens) in a protective plastic tray. 
Kutija s dvije napunjene brizgalice od 125 mikrograma (sivo označene brizgalice) u zaštitnom plastičnom spremniku.
You need to inject Plegridy once every 2 weeks. 
Plegridy morate primijeniti jednom svaka 2 tjedna.
Regular thyroid function tests are recommended in patients with a history of thyroid dysfunction or as clinically indicated. 
Bolesnicima koji su prethodno imali disfunkciju štitnjače preporučuje se redovni test funkcije štitnjače ili kako je klinički indicirano.
- The 125 micrograms grey pens are provided in a pack containing either two or six pre-filled pens. 
- Sive brizgalice od 125 mikrograma nalaze se u pakiranju koje sadrži bilo dvije ili šest napunjenih brizgalica.
The incidence of potentially clinically significant decreases in lymphocyte counts (<0.5 x 109/L) (<1%), neutrophil counts (≤1.0 x 109/L) (<1%) and platelet counts (≤100 x 109/L) (≤1%) was similar in Plegridy-treated patients compared to placebotreated patients. 
Incidencija potencijalno klinički značajnog pada broja limfocita (<0,5 x 109/l) (<1%), broja neutrofila (≤1,0 x 109/l) (<1%), i broja trombocita
Multipacks containing 6 (3 packs of 2) 125 microgram pre-filled pens (grey labelled pens). 
Višestruko pakiranje sadrži 6 (3 pakiranja od 2) napunjenih brizgalica od 125 mikrograma (sivo označene brizgalice).
1 mL pre-filled syringe made of glass (Type I) with a bromobutyl rubber stopper and thermoplastic and polypropylene rigid needle shield, containing 0.5 mL of solution. 
Napunjena štrcaljka volumena 1 ml od stakla (tip I) s brombutilnim gumenim čepom i termoplastičnim i polipropilenskim krutim štitnikom igle, koja sadrži 0,5 ml otopine.
Sodium acetate trihydrate, acetic acid glacial, arginine hydrochloride, polysorbate 20, water for injections. 
POPIS POMOĆNIH TVARI Natrijev acetat trihidrat, acetatna kiselina ledena, argininklorid, polisorbat 20 i voda za injekcije.
How long to use Plegridy 
Kako dugo primjenjivati Plegridy
Do not rest the pen on the injection site until you are ready to inject. 
Nemojte naslanjati brizgalicu na mjesto za injekciju prije nego što budete spremni ubrizgati lijek.
The pharmacokinetics of peginterferon beta-1a has not been evaluated in patients with hepatic insufficiency. 
Farmakokinetika peginterferona beta-1a nije procijenjena u bolesnika koji imaju insuficijenciju jetre.
Do not use the pen if it has been dropped or is visibly damaged. 
Nemojte upotrijebiti brizgalicu ako je ispala ili ima vidljiva oštećenja.
Swelling around the face (lips, tongue or throat) Skin rashes or redness 
- otežano disanje - oticanje u području lica (usana, jezika ili grla) - osip ili crvenilo kože
If a refrigerator is not available, syringes can be left at room temperature (up to 25°C) for up to 30 days. 
Ako hladnjak nije dostupan, štrcaljke se može ostaviti na sobnoj temperaturi (do 25°C) do 30 dana.
- The 125 micrograms grey syringes are provided in a pack containing either two or six pre-filled syringes. 
- Sive štrcaljke od 125 mikrograma nalaze se u pakiranju koje sadrži bilo dvije ili šest napunjenih štrcaljki.
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all). 
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p=0,0459), i MR ishode (nove/povećane
Caution - Do not recap the Plegridy pre-filled syringe. 
Oprez - Nemojte vraćati pokrov na napunjenu štrcaljku Plegridyja.
The syringe inside the pen is a 1 mL pre-filled syringe made of glass (Type I) with a bromobutyl rubber stopper and thermoplastic and polypropylene rigid needle shield, containing 0.5 mL of solution. 
Štrcaljka unutar brizgalice je napunjena štrcaljka volumena 1 ml od stakla (tip I) s brombutilnim gumenim čepom i termoplastičnim i polipropilenskim čvrstim štitnikom igle, koja sadrži 0,5 ml otopine.
Plegridy is an interferon beta-1a conjugated with a single, linear molecule of 20,000 Da methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde (20 kDa mPEG-O-2-methylpropionaldehyde) at a degree of substitution of 1 mole of polymer/mole of protein. 
Plegridy je interferon beta-1a konjugiran s jednom, linearnom molekulom metoksipoli(etilenglikol)-O-2-metilpropionaldehida od 20 000 Da (20 kDa mPEG-O-2-metilpropionaldehid) stupnja supstitucije od 1 mola polimera po molu proteina.
The serum half-life of peginterferon beta-1a is prolonged compared with non-pegylated interferon beta-1a. 
Poluvijek peginterferona beta-1a u serumu je produljen u usporedbi s nepegiliranim interferonom beta-1a.
63 micrograms, choose orange syringe 
63 mikrograma, odaberite narančastu štrcaljku
Full dose injection: 125 micrograms, choose grey pen 
Injekcija pune doze: 125 mikrograma, odaberite sivu brizgalicu
Influenza-like illness was experienced by 47% of patients receiving Plegridy 125 micrograms every 2 weeks and 13% of patients receiving placebo. 
Bolest nalik gripi razvilo je 47% bolesnika koji su primali 125 mikrograma Plegridyja svaka 2 tjedna i 13% bolesnika koji su dobivali placebo.
Across relapse and MRI endpoints Plegridy 125 micrograms every two weeks showed a numerically greater treatment effect over the Plegridy every four weeks dosing regimen at year 1. 
125 mikrograma Plegridyja svaka dva tjedna pokazala je brojčano veći učinak liječenja nego Plegridy u režimu doziranja od svaka četiri tjedna nakon 1 godine.
Blue 
Plava
1 Adverse reactions derived only during post marketing experience 
1 Nuspojave zabilježene samo nakon stavljanja lijeka u promet.
Caution should be used and close monitoring considered when administering Plegridy to patients with severe hepatic impairment. 
Potreban je oprez i pomno praćenje kod primjene Plegridyja u bolesnika s teškim oštećenjem jetre.
Do not reuse your Plegridy pen. 
Nemojte ponovno upotrijebiti štrcaljku Plegridyja.
• Plegridy pre-filled syringe is for injecting the medicine under the skin only (subcutaneous) 
• Napunjena štrcaljka Plegridyja namijenjena je ubrizgavanju lijeka samo pod kožu (supkutano).
Alternate the sites you use for injections. 
Mijenjajte mjesta davanja injekcija.
No dosage adjustments are necessary in patients with renal impairment based on study data in mild, moderate, and severe renal impairment and end stage renal disease (see sections 4.4 and 5.2). 
Na temelju podataka iz ispitivanja za bolesnike s blagim, umjerenim i teškim oštećenjem bubrega te terminalnim bubrežnim zatajenjem nije potrebna prilagodba doze u bolesnika s oštećenjem bubrega (vidjeti dijelove 4.4 i 5.2).
Warnings and precautions Talk to your doctor if you have ever had: 
Upozorenja i mjere opreza Obratite se liječniku ako ste ikada imali: - depresiju ili probleme koji utječu na Vaše raspoloženje - misli o samoubojstvu
EXP If a refrigerator is not available, pens can be left at room temperature (up to 25°C) for up to 30 days. 
EXP Ako hladnjak nije dostupan, brizgalice se može ostaviti na sobnoj temperaturi (do 25°C) do 30 dana.
Plegridy has not been studied in patients with hepatic impairment (see section 4.4). 
Plegridy nije ispitivan u bolesnika s oštećenjem funkcije jetre (vidjeti dio 4.4).
Which dose 
Koju dozu
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Pre-Filled Syringe Double Lid Initiation Pack 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Pakiranje za početak liječenja s napunjenim štrcaljkama i dvostrukim poklopcem
Close the pack and put back in the fridge after removing one pen. 
Nakon što ste izvadili jednu brizgalicu, zatvorite pakiranje i vratite ga u hladnjak.
numbness in the face, arms or legs - Acute or chronic pain, bladder and bowel problems, sexual problems and problems with vision - Difficulty thinking and concentrating, depression. 
- akutnu ili kroničnu bol, probleme s mjehurom i crijevima, seksualne probleme i poteškoće s vidom
Of a total of 1468 patients, 658 patients continued at least 4 years of treatment with Plegridy. 
njih 658 nastavilo je liječenje Plegridyjem najmanje 4 godine.
Skin and subcutaneous tissue disorders 
Poremećaji kože i potkožnog tkiva alopecija$
Hypersensitivity events were reported in 16% of patients treated with Plegridy 125 micrograms every 2 weeks and 14% of patients who received placebo. 
Slučajevi preosjetljivosti prijavljeni su u 16% bolesnika koji su primali 125 mikrograma Plegridyja svaka 2 tjedna i 14% bolesnika koji su dobivali placebo.